Cell Source, Inc.

Cell Source, Inc.verified

CLCS

Price:

$0.57248

Market Cap:

$24.88M

Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, ...[Read more]

Industry

Biotechnology

IPO Date

2014-05-01

Stock Exchange

PNK

Ticker

CLCS

The Enterprise Value as of November 2024 (TTM) for Cell Source, Inc. (CLCS) is 34.64M

According to Cell Source, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 34.64M. This represents a change of 68.15% compared to the average of 20.60M of the last 4 quarters.

Cell Source, Inc. (CLCS) Historical Enterprise Value (quarterly & annually)

How has CLCS Enterprise Value performed in the past?

The mean historical Enterprise Value of Cell Source, Inc. over the last ten years is 30.25M. The current 34.64M Enterprise Value has changed 11.35% with respect to the historical average. Over the past ten years (40 quarters), CLCS's Enterprise Value was at its highest in in the June 2021 quarter at 70.49M. The Enterprise Value was at its lowest in in the September 2022 quarter at 7.20M.

Quarterly (TTM)
Annual

Average

30.25M

Median

28.66M

Minimum

8.64M

Maximum

62.76M

Cell Source, Inc. (CLCS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Cell Source, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 203.36%

Maximum Annual Enterprise Value = 62.76M

Minimum Annual Increase = -60.09%

Minimum Annual Enterprise Value = 8.64M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202323.59M-36.74%
202237.29M-23.53%
202148.77M-22.30%
202062.76M86.05%
201933.73M45.01%
201823.26M169.11%
20178.64M-41.88%
201614.87M-60.09%
201537.27M203.36%
201412.28M6.78%

Cell Source, Inc. (CLCS) Average Enterprise Value

How has CLCS Enterprise Value performed in the past?

The current Enterprise Value of Cell Source, Inc. (CLCS) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

36.55M

5-year avg

41.23M

10-year avg

30.25M

Cell Source, Inc. (CLCS) Enterprise Value vs. Peers

How is CLCS’s Enterprise Value compared to its peers?

Cell Source, Inc.’s Enterprise Value is greater than Emmaus Life Sciences, Inc. (33.54M), greater than Adhera Therapeutics, Inc. (10.81M), greater than PolarityTE, Inc. (-6308329.00), less than ZIVO Bioscience, Inc. (73.95M), greater than Pasithea Therapeutics Corp. (-5435245.00), less than Nutriband Inc. (46.88M), greater than MediciNova, Inc. (-41974173594.00), less than Eliem Therapeutics, Inc. (119.64M), greater than Panbela Therapeutics, Inc. (4.75M), greater than Virpax Pharmaceuticals, Inc. (4.57M), greater than Revelation Biosciences, Inc. (-3300245.00), greater than Biodexa Pharmaceuticals Plc (-2820215.62), less than Praxis Precision Medicines, Inc. (1.22B), greater than Cardio Diagnostics Holdings, Inc. (9.47M), less than Sigilon Therapeutics, Inc. (42.21M), greater than Sonnet BioTherapeutics Holdings, Inc. (-907921.00), greater than ZyVersa Therapeutics, Inc. (2.53M), less than X4 Pharmaceuticals, Inc. (38.44M), greater than eFFECTOR Therapeutics, Inc. (4.74M), less than Landos Biopharma, Inc. (42.62M), greater than Apexigen, Inc. (-5121682.00), greater than Navidea Biopharmaceuticals, Inc. (-2504975.00), greater than Angion Biomedica Corp. (22.43M),

Build a custom stock screener for Cell Source, Inc. (CLCS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cell Source, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cell Source, Inc. (CLCS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cell Source, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Cell Source, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Cell Source, Inc. (CLCS)?

What is the 3-year average Enterprise Value for Cell Source, Inc. (CLCS)?

What is the 5-year average Enterprise Value for Cell Source, Inc. (CLCS)?

How does the current Enterprise Value for Cell Source, Inc. (CLCS) compare to its historical average?